Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

A. Charehbili, S. van de Ven, V. T. H. B. M. Smit, E. Meershoek-Klein Kranenbarg, N. A. T. Hamdy, H. Putter, J. B. Heijns, L. J. C. van Warmerdam, L. Kessels, M. Dercksen, M. J. Pepels, E. Maartense, H. W. M. van Laarhoven, B. Vriens, M. N. Wasser, A. E. van Leeuwen-Stok, G. J. Liefers, C. J. H. van de Velde, J. W. R. Nortier, J. R. Kroep

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)998-1004
JournalAnnals of Oncology
Volume25
Issue number5
DOIs
Publication statusPublished - May 2014

Keywords

  • neoadjuvant chemotherapy
  • zoledronic acid
  • bisphosphonates
  • menopausal status

Cite this

Charehbili, A., van de Ven, S., Smit, V. T. H. B. M., Meershoek-Klein Kranenbarg, E., Hamdy, N. A. T., Putter, H., Heijns, J. B., van Warmerdam, L. J. C., Kessels, L., Dercksen, M., Pepels, M. J., Maartense, E., van Laarhoven, H. W. M., Vriens, B., Wasser, M. N., van Leeuwen-Stok, A. E., Liefers, G. J., van de Velde, C. J. H., Nortier, J. W. R., & Kroep, J. R. (2014). Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Annals of Oncology, 25(5), 998-1004. https://doi.org/10.1093/annonc/mdu102